SCHEMBL3275729

SCHEMBL3275729

CCN(CC)c1cc(-c2nc(-c3ccc(CCN)cc3)no2)cc(C)n1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 9/20 0.44
NPC1 O15118 5/20 0.44
RAB9A P51151 5/20 0.44
ALDH1A1 P00352 2/20 0.44
MAPT P10636 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NFKB1 P19838 2/20 0.44
NFKB2 Q00653 2/20 0.44
RELA Q04206 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
S1PR3 Q99500 4/20 0.42
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.39
GAA P10253 1/20 0.38
S1PR4 O95977 1/20 0.36
S1PR5 Q9H228 1/20 0.36
NR1H4 Q96RI1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3277417 0.89 S1PR1 (0.55) S1PR1NPC1RAB9AALDH1A1MAPT
SCHEMBL13384705 0.88 RAB9A (0.54) S1PR1NPC1RAB9AALDH1A1MAPT
SCHEMBL3282469 0.86 S1PR1 (0.53) S1PR1NPC1RAB9AALDH1A1MAPT
SCHEMBL13384700 0.86 NPC1 (0.51) S1PR1NPC1RAB9AALDH1A1MAPT
SCHEMBL3276319 0.83 S1PR1 (0.44) S1PR1NPC1RAB9AALDH1A1MAPT
SCHEMBL3280060 0.82 S1PR1 (0.47) S1PR1NPC1RAB9AALDH1A1MAPT
SCHEMBL3086366 0.81 S1PR1 (0.40) S1PR1NPC1RAB9AALDH1A1MAPT
SCHEMBL3281197 0.81 S1PR1 (0.44) S1PR1NPC1RAB9AALDH1A1MAPT
SCHEMBL3277047 0.81 S1PR1 (0.51) S1PR1S1PR3POLBNR1H4
SCHEMBL1425008 0.79 S1PR1 (0.52) S1PR1NPC1RAB9AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125797-B1 AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2014-01-15 EP disclosed
US-8592460-B2 Amino-pyridine derivatives as S1P1 /EDG1 receptor agonists ACTELION PHARMACEUTICALS LTD. (CH) 2013-11-26 US disclosed
CN-101627034-B amino-pyridine derivatives as S1P1/EDG1 receptor agonists ACTELION PHARMACEUTICALS LTD 2013-05-15 CN disclosed
US-20100087417-A1 AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2010-04-08 US disclosed
EP-2125797-A1 AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS Actelion Pharmaceuticals Ltd. (CH) 2009-12-02 EP disclosed
WO-2008114157-A1 AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087417-A1 AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS S1PR1, S1PR3, S1PR4 S1PR1 1/4885NPC1 1368/4885RAB9A 2455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.